NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, ladies and gentlemen. Welcome to the fourth quarter of fiscal year 2025 Financial Results Conference Call for Norah One Medical Technologies Corporation. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa, and Ron McClurg, the company's Chief Financial Officer. Before I turn the call over to Mr. Rosa, I'd like to remind you that this conference call will include forward-looking statements within the meaning of U.S. federal securities laws with respect to future operations, financial results, events, trends, and performance, which are based on management's beliefs and assumptions as of today's call. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors which may cause actual results to differ materially from those implied by such statements. To see NORA 1's financial results press release and SEC filings, for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, NORA 1 undertakes no obligation to update such forward-looking statements. With that, I will turn the call over to Mr. Dave Rosa, CEO of NORA 1. Please go ahead, sir. Thank you, Operator, and thank you to everyone for joining us today. I'd like to welcome you to our fourth quarter fiscal 2025 financial results conference call. Fiscal year 2025 was the most successful year in the history of Neuron Medical Technologies Corporation and an inflection point for our company. I'd like to start today with a brief overview of the most significant milestones we achieved in fiscal year 2025. Financially, we saw record product sales growth of 163% to $9.1 million. Reduced operating expenses significantly improved our product gross margins to 56.5% and strengthened the ...